Menu

rss
Heart 98:1258 doi:10.1136/heartjnl-2012-302270
  • PostScript
  • Correspondence

Industry-sponsored cost-effectiveness study of TAVI

  1. Michael A Crilly2
  1. 1Public Health Directorate, NHS Grampian, Aberdeen, UK
  2. 2Population Health, Aberdeen University Medical School, Aberdeen, UK
  1. Correspondence to Mr Christopher Littlejohn, Specialty Registrar in Public Health, NHS Grampian, Summerfield House, 2 Eday Road, Aberdeen. AB15 6RE

To the Editor: The potential cost-effectiveness (CE) of adopting innovative procedures within a publically funded healthcare system is a recurring issue.1 Trans-catheter aortic valve insertion (TAVI) is not currently provided by the devolved National Health Service in Scotland, although a single high quality randomised controlled clinical trial (RCT) has demonstrated that TAVI is a clinically effective intervention for reducing the risk of death in older patients with severe aortic stenosis considered unfit for standard surgery.2 The recently published CE analysis of TAVI reports an incremental …

[Full text of this article]

This Article

  1. Extract
  2. Full text
  3. PDF
  4. All Versions of this Article:
    1. heartjnl-2012-302270v1
    2. 98/16/1258-a most recent

Responses

  1. Submit a response
  2. No responses published

Social bookmarking

Register for free content


Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of Heart.
View free sample issue >>

Free archive
The full back archive is now available for Heart. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
Register to access the free archive >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.